bladder cancer, prostatectomy

Prostate cancer patients may have long-term complications from treatment
Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.
Prostate Cancer Treatment Associated With More Complications
Researchers conducted a cohort study to try to characterize long-term treatment-related adverse effects and complications in patients treated for prostate cancer.
Long-term risks from prostate cancer treatment detailed in new report
The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after treatment ends. The largest comprehensive analysis reporting long-term risks from such treatment relative to the risks faced by a control group of untreated men has just been published in the journal JAMA Oncology.
Complications From Prostate Cancer Therapy Can Be Serious and Long-Term
Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds. Surgery for prostate cancers increases a man’s risk of urinary or sexual complications more than sevenfold,
Long-Term Complications After Prostate Cancer Treatment Not Uncommon
Prostate cancer (PCA) treatment is associated with increased rates of complications in the 12 years after treatment, according to a study published online Nov. 7 in JAMA Oncology. Joseph M. Unger, Ph.
emjreviews.com2d
No Survival Benefit of Extended Lymphadenectomy in Bladder Cancer Surgery
A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...
Cure Today3d
FDA Approval Withdrawal of Trodelvy Leaves Fewer Bladder Cancer Options
The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.
News Medical on MSN1d
Novel bladder cancer treatment gains MHRA approval in the UK
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...
PharmTech2d
J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer
Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024 ...
Cure Today3d
Whole Pelvis Radiation in Muscle-Invasive Bladder Cancer May Improve Survival
Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.
Hosted on MSN22h
What to Expect From a Bladder Ultrasound
A bladder ultrasound is a noninvasive imaging technique used to check for abnormalities in the urinary bladder. It ...
Risk factors found for neurogenic bladder after rectal cancer surgery
Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...
Should You Get a Cancer Vaccine?
Though they may seem like something from the future, these five cancer vaccines are available now. Here are details about who ...
PharmiWeb3d
MHRA grants marketing authorisation to J&J’s bladder cancer therapy BALVERSA® (erdafitinib)
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...
GlobalData on MSN1d
KFSHRC partners with University of Birmingham for bladder cancer diagnosis
King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...